Related Experiment Videos
Redefining medical treatment in the management of unstable angina
E Braunwald1, R M Califf, C P Cannon
1Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Insights
New guidelines for unstable angina management recommend cardiac troponin testing and specific therapies. These include intravenous glycoprotein (GP) IIb-IIIa inhibitors and low-molecular-weight heparin for improved patient outcomes.
Area of Science:
- Cardiology
- Clinical Medicine
- Biochemistry
Background:
- Guidelines for unstable angina were published in 1994.
- Significant advancements have occurred since then.
- Biomarkers and therapeutic agents have evolved.
Purpose of the Study:
- To update the management strategies for unstable angina.
- To incorporate recent evidence on diagnostic and therapeutic options.
- To provide recommendations for current clinical practice.
Main Methods:
- Review of recent studies on cardiac biomarkers.
- Evaluation of clinical trial data for new antiplatelet and anticoagulant agents.
- Synthesis of evidence to inform guideline revisions.
Main Results:
- Cardiac-specific troponins T and I demonstrate significant prognostic value.
- Intravenous glycoprotein (GP) IIb-IIIa inhibitors show substantial clinical benefits.
- Low-molecular-weight heparins, such as enoxaparin, are effective.
Conclusions:
- Measuring serum cardiac troponin (T or I) is recommended.
- Intravenous GP IIb-IIIa inhibitors should be considered in standard management.
- Low-molecular-weight heparin use is advised for unstable angina patients.
Abstract:
In 1994, the Agency for Health Care Policy and Research sponsored the development of guidelines for diagnosing and managing patients with unstable angina. Since their publication, several important developments have occurred. The prognostic value of biochemical assays for cardiac-specific troponins T and I have been shown in many studies. The possible role for C-reactive protein in determining prognosis deserves further investigation. Substantial clinical benefits have been obtained with intravenous inhibitors of the platelet glycoprotein (GP) IIb-IIIa receptor (abciximab, eptifibatide, tirofiban) and with one of the low-molecular-weight heparins (enoxaparin). The therapeutic potential of other low-molecular-weight heparins, direct thrombin inhibitors, and oral GP IIb-IIIa inhibitors remains to be clarified. On the basis of this evidence, consideration should be given to measuring serum levels of a cardiac troponin (either T or I) and using intravenous GP IIb-IIIa inhibitors and low-molecular-weight heparin in the standard management of patients with unstable angina.